Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses APGE in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named APGE in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Henderson | $700,000 | $0 | $0 | $0 | $591,500 | $0 | $0 | $1,291,500 |
| Chief Executive Officer | ||||||||
| Carl Dambkowski | 540,000 | 0 | 0 | 0 | 315,900 | 0 | 0 | 855,900 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Michael Henderson | $1,291,500 | $13,207,682 | $8,671,208 | −11,916,182 |
| Carl Dambkowski | 855,900 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Michael Henderson | RSU | 60,497 | — | $4,566,314 |
| Michael Henderson | RSU | 64,724 | — | 4,885,368 |
| Michael Henderson | Option | 87,673 | 22.86 | — |
| Michael Henderson | RSU | 71,845 | — | 5,422,861 |
| Carl Dambkowski | RSU | 42,199 | — | 3,185,181 |
| Michael Henderson | Option | 267,777 | 49.07 | — |
| Carl Dambkowski | Option | 93,722 | 49.07 | — |
| Michael Henderson | RSU | 60,338 | — | 4,554,312 |
| Michael Henderson | Option | 199,256 | 22.86 | — |
| Carl Dambkowski | RSU | 24,749 | — | 1,868,055 |
| Carl Dambkowski | Option | 87,673 | 22.86 | — |
| Michael Henderson | Option | 93,722 | 49.07 | — |
The executive compensation program is intended to align executive compensation with business objectives and to attract, retain, and reward executive officers who contribute to long-term success. The program emphasizes a high percentage of at-risk pay, linking short-term and long-term cash and equity incentives to measurable corporate and individual performance goals to reinforce a performance-driven culture.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Mark C. McKennaIndependent · Board Chair · Compensation Committee (Chair) · Nominating Committee | $87,231 | — | $399,988 | — | — | $487,219 |
| Jennifer FoxIndependent · Audit Committee (Chair) · Compensation Committee | 64,038 | — | 399,988 | — | — | 464,026 |
| William (BJ) Jones JrIndependent · Compensation · Nominating | 55,423 | — | 399,988 | — | — | 455,411 |
| Andrew Gottesdiener, M.DIndependent · Audit · Not standing for re-election | 48,846 | — | 399,988 | — | — | 448,834 |
| Peter HarwinIndependent · Audit Committee · Not standing for re-election | 48,846 | — | 399,988 | — | — | 448,834 |
| Nimish ShahIndependent · Nominating Committee | 44,538 | — | 399,988 | — | — | 444,526 |
| Lisa Bollinger, M.DIndependent · Audit · Nominating | 44,538 | — | 399,988 | — | — | 444,526 |
| Tomas KiselakIndependent | 40,000 | — | 399,988 | — | — | 439,988 |
| Michael Henderson, M.DEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $433,460 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $433,460 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Apogee Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Apogee Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Arcellx | 2024 | Rami Elghandour | $653,288 | $9,342,069 | $10,850,151 | $0 | $21,402,668 |
| 2 | Viking Therapeutics | 2025 | Brian Lian | 672,000 | 17,756,817 | 2,468,016 | 373,000 | 21,269,833 |
| 3 | Immunovant | 2026 | Eric Venker | 636,618 | 0 | 19,010,639 | 0 | 20,158,767 |
| 4 | Vaxcyte | 2025 | Grant Pickering | 800,000 | 4,300,159 | 8,714,048 | 630,000 | 14,458,937 |
| 5 | Avidity Biosciences | 2024 | Sarah Boyce | 659,900 | 10,748,480 | 2,157,090 | 594,000 | 14,176,480 |
| 6 | Nuvalent | 2025 | James Porter | 652,100 | 4,392,563 | 5,857,906 | 469,512 | 11,393,602 |
| 7 | Akero Therapeutics | 2024 | Andrew Cheng | 686,000 | 2,879,155 | 6,489,100 | 411,600 | 10,465,855 |
| 8 | IDEAYA Biosciences | 2025 | Yujiro Hata | 700,000 | 0 | 8,418,840 | 378,000 | 9,512,640 |
| 9 | Arrowhead Pharmaceuticals | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 10 | Kymera Therapeutics | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 11 | Structure Therapeutics | 2025 | Raymond Stevens | 672,094 | 2,387,996 | 4,846,926 | 508,871 | 8,429,887 |
| 12 | Spyre Therapeutics | 2025 | Cameron Turtle | 665,000 | 0 | 5,552,886 | 475,475 | 6,707,361 |
| 13 | Celldex Therapeutics | 2025 | Anthony Marucci | 785,804 | 0 | 4,027,590 | 0 | 5,366,709 |
| 14 | Neumora Therapeutics | 2025 | Paul Berns | 700,000 | 0 | 3,326,181 | 504,000 | 4,562,461 |
| 15 | Dyne Therapeutics | 2025 | John Cox | 721,000 | 0 | 937,893 | 410,970 | 2,076,868 |
| 16 | Apogee Therapeutics | 2025 | Michael Henderson | 700,000 | 0 | 0 | 591,500 | 1,291,500 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Apogee Therapeutics | not disclosed | Option 100 | not disclosed | Alpine Rewards |
| Akero Therapeutics | 100% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Arcellx | 140% | not disclosed | No | Meridian Compensation Partners, LLC |
| Arrowhead Pharmaceuticals | 125% | PSU 70 · RSU 30 | not disclosed | Compensia |
| Avidity Biosciences | not disclosed | PSU 100 · Option 80 · RSU 20 | not disclosed | Alpine Rewards, LLC |
| Celldex Therapeutics | 100% | Options 100 | not disclosed | Aon (Human Capital Solutions practice, a division of Aon plc) |
| Dyne Therapeutics | 95% | not disclosed | not disclosed | Alpine Rewards, LLC |
| IDEAYA Biosciences | 90% | Options 100 | not disclosed | Aon (Aon plc, Talent Solutions practice) |
| Immunovant | 110% | not disclosed | No | Compensia |
| Kymera Therapeutics | 125% | not disclosed | No | Alpine Rewards |
| Neumora Therapeutics | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| Nuvalent | 120% | not disclosed | No | Alpine Rewards |
| Spyre Therapeutics | 130% | Options 100 | not disclosed | Alpine Rewards |
| Structure Therapeutics | 125% | Options 67 · RSU 33 | No | Aon |
| Vaxcyte | 105% | not disclosed | not disclosed | Pay Governance |
| Viking Therapeutics | not disclosed | not disclosed | No | Aon, plc (Aon) |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Michael Henderson | DEF 14A | 2026-04-24 | 0001193125-26-177342 | Section “Executive Compensation”. As printed: 1,291,500. Filing ↗ |
| 2 | Section 01, Carl Dambkowski | DEF 14A | 2026-04-24 | 0001193125-26-177342 | Section “Executive Compensation”. As printed: 855,900. Filing ↗ |
| 3 | Section 08, Mark C. McKenna | DEF 14A | 2026-04-24 | 0001193125-26-177342 | Section “Director Compensation”. As printed: 487,219. Filing ↗machine: span 338224–338433 |
| 4 | Section 08, Jennifer Fox | DEF 14A | 2026-04-24 | 0001193125-26-177342 | Section “Director Compensation”. As printed: 464,026. Filing ↗machine: span 314236–314445 |
| 5 | Section 08, William (BJ) Jones Jr | DEF 14A | 2026-04-24 | 0001193125-26-177342 | Section “Director Compensation”. As printed: 455,411. Filing ↗machine: span 328641–328850 |
| 6 | Section 08, Andrew Gottesdiener, M.D | DEF 14A | 2026-04-24 | 0001193125-26-177342 | Section “Director Compensation”. As printed: 448,834. Filing ↗machine: span 319044–319253 |
| 7 | Section 08, Peter Harwin | DEF 14A | 2026-04-24 | 0001193125-26-177342 | Section “Director Compensation”. As printed: 448,834. Filing ↗machine: span 323839–324048 |
| 8 | Section 08, Nimish Shah | DEF 14A | 2026-04-24 | 0001193125-26-177342 | Section “Director Compensation”. As printed: 444,526. Filing ↗machine: span 343015–343224 |
| 9 | Section 08, Lisa Bollinger, M.D | DEF 14A | 2026-04-24 | 0001193125-26-177342 | Section “Director Compensation”. As printed: 444,526. Filing ↗machine: span 309445–309654 |
| 10 | Section 08, Tomas Kiselak | DEF 14A | 2026-04-24 | 0001193125-26-177342 | Section “Director Compensation”. As printed: 439,988. Filing ↗machine: span 333433–333642 |
| 11 | Section 08, Michael Henderson, M.D | DEF 14A | 2026-04-24 | 0001193125-26-177342 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 13 | Section 09b board cost (computed) | Computed | — | computed | Cash 433,460 + equity 0 + all other 0 = 433,460, summed across the director compensation table rows.machine: formula: Σ = 433,460 |
| 14 | Arcellx, Section 10b CEO total | DEF 14A | 2025-04-17 | 0001193125-25-084363 | CEO total compensation as printed in Arcellx's own proxy. As printed: 21,402,668. Filing ↗machine: r2 · c31 · span 471887–471897 |
| 15 | Viking Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-01 | 0001193125-26-137915 | CEO total compensation as printed in Viking Therapeutics's own proxy. As printed: 21,269,833. Filing ↗machine: t8 · r2 · c17 · span 395920–395930 |
| 16 | Immunovant, Section 10b CEO total | DEF 14A | 2026-07-22 | 0001764013-26-000092 | CEO total compensation as printed in Immunovant's own proxy. As printed: 20,158,767. Filing ↗machine: span 465716–465726 |
| 17 | Vaxcyte, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173672 | CEO total compensation as printed in Vaxcyte's own proxy. As printed: 14,458,937. Filing ↗machine: r2 · c30 · span 561197–561207 |
| 18 | Avidity Biosciences, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001599901-25-000092 | CEO total compensation as printed in Avidity Biosciences's own proxy. As printed: 14,176,480. Filing ↗machine: r2 · c48 · span 430390–430400 |
| 19 | Nuvalent, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001861560-26-000013 | CEO total compensation as printed in Nuvalent's own proxy. As printed: 11,393,602. Filing ↗machine: r2 · c14 · span 689237–689247 |
| 20 | Akero Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-28 | 0000950170-25-058964 | CEO total compensation as printed in Akero Therapeutics's own proxy. As printed: 10,465,855. Filing ↗machine: t13 · r2 · c14 · span 492349–492359 |
| 21 | IDEAYA Biosciences, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191501 | CEO total compensation as printed in IDEAYA Biosciences's own proxy. As printed: 9,512,640. Filing ↗machine: r2 · c14 · span 627310–627319 |
| 22 | Arrowhead Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-01-27 | 0000879407-26-000019 | CEO total compensation as printed in Arrowhead Pharmaceuticals's own proxy. As printed: 9,029,861. Filing ↗machine: span 692475–692484 |
| 23 | Kymera Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191495 | CEO total compensation as printed in Kymera Therapeutics's own proxy. As printed: 8,545,609. Filing ↗machine: r2 · c14 · span 676137–676146 |
| 24 | Structure Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047740 | CEO total compensation as printed in Structure Therapeutics's own proxy. As printed: 8,429,887. Filing ↗machine: r1 · c47 · span 552927–552936 |
| 25 | Spyre Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-10 | 0001636282-26-000039 | CEO total compensation as printed in Spyre Therapeutics's own proxy. As printed: 6,707,361. Filing ↗machine: r2 · c48 · span 393018–393027 |
| 26 | Celldex Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001104659-26-050884 | CEO total compensation as printed in Celldex Therapeutics's own proxy. As printed: 5,366,709. Filing ↗machine: r1 · c54 · span 1024857–1024866 |
| 27 | Neumora Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-161489 | CEO total compensation as printed in Neumora Therapeutics's own proxy. As printed: 4,562,461. Filing ↗machine: r2 · c29 · span 444810–444819 |
| 28 | Dyne Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173655 | CEO total compensation as printed in Dyne Therapeutics's own proxy. As printed: 2,076,868. Filing ↗machine: r3 · c24 · span 816239–816248 |
| 29 | Apogee Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177342 | CEO total compensation as printed in Apogee Therapeutics's own proxy. As printed: 1,291,500. Filing ↗ |
| 30 | Section 10a, Akero Therapeutics reciprocity | DEF 14A | — | 0000950170-25-058964 | Akero Therapeutics's most recent proxy was read; its disclosed peer group does not include Apogee Therapeutics. Filing ↗ |
| 31 | Section 10a, Structure Therapeutics reciprocity | DEF 14A | — | 0001104659-26-047740 | Structure Therapeutics's most recent proxy was read; its disclosed peer group does not include Apogee Therapeutics. Filing ↗ |
| 32 | Section 10a, Arcellx reciprocity | DEF 14A | — | 0001193125-25-084363 | Arcellx's most recent proxy was read; its disclosed peer group does not include Apogee Therapeutics. Filing ↗ |
| 33 | Section 10a, Vaxcyte reciprocity | DEF 14A | — | 0001193125-26-173672 | Vaxcyte's most recent proxy was read; its disclosed peer group does not include Apogee Therapeutics. Filing ↗ |
| 34 | Section 10a, Dyne Therapeutics reciprocity | DEF 14A | — | 0001193125-26-173655 | Dyne Therapeutics's most recent proxy was read; its disclosed peer group does not include Apogee Therapeutics. Filing ↗ |
| 35 | Section 10a, Celldex Therapeutics reciprocity | DEF 14A | — | 0001104659-26-050884 | Celldex Therapeutics's most recent proxy was read; its disclosed peer group does not include Apogee Therapeutics. Filing ↗ |
| 36 | Section 10a, Avidity Biosciences reciprocity | DEF 14A | — | 0001599901-25-000092 | Avidity Biosciences's most recent proxy was read; its disclosed peer group does not include Apogee Therapeutics. Filing ↗ |
| 37 | Section 10a, Kymera Therapeutics reciprocity | DEF 14A | — | 0001193125-26-191495 | Kymera Therapeutics's most recent proxy was read; its disclosed peer group does not include Apogee Therapeutics. Filing ↗ |
| 38 | Section 10a, Arrowhead Pharmaceuticals reciprocity | DEF 14A | — | 0000879407-26-000019 | Arrowhead Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Apogee Therapeutics. Filing ↗ |
| 39 | Section 10a, IDEAYA Biosciences reciprocity | DEF 14A | — | 0001193125-26-191501 | IDEAYA Biosciences's most recent proxy was read; its disclosed peer group does not include Apogee Therapeutics. Filing ↗ |
| 40 | Section 10a, Spyre Therapeutics reciprocity | DEF 14A | — | 0001636282-26-000039 | Spyre Therapeutics names Apogee Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 41 | Section 10a, Viking Therapeutics reciprocity | DEF 14A | — | 0001193125-26-137915 | Viking Therapeutics's most recent proxy was read; its disclosed peer group does not include Apogee Therapeutics. Filing ↗ |
| 42 | Section 10a, Immunovant reciprocity | DEF 14A | — | 0001764013-26-000092 | Immunovant names Apogee Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 43 | Section 10a, Nuvalent reciprocity | DEF 14A | — | 0001861560-26-000013 | Nuvalent's most recent proxy was read; its disclosed peer group does not include Apogee Therapeutics. Filing ↗ |